ProfileGDS5678 / 1449321_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 21% 21% 21% 20% 20% 21% 20% 20% 20% 20% 21% 20% 20% 26% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5261721
GSM967853U87-EV human glioblastoma xenograft - Control 22.4897821
GSM967854U87-EV human glioblastoma xenograft - Control 32.4939621
GSM967855U87-EV human glioblastoma xenograft - Control 42.4283220
GSM967856U87-EV human glioblastoma xenograft - Control 52.4314320
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5569321
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5190520
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4664520
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4503920
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4760720
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4762321
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4542120
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4797520
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5896226